The largest prospective warfarin-treated cohort supports genetic forecasting
Top Cited Papers
Open Access
- 22 January 2009
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 113 (4), 784-792
- https://doi.org/10.1182/blood-2008-04-149070
Abstract
Genetic variants of cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) are known to influence warfarin dose, but the effect of other genes has not been fully elucidated. We genotyped 183 polymorphisms in 29 candidate genes in 1496 Swedish patients starting warfarin treatment, and tested for association with response. CYP2C9*2 and *3 explained 12% (P = 6.63 × 10−34) of the variation in warfarin dose, while a single VKORC1 SNP explained 30% (P = 9.82 × 10−100). No SNP outside the CYP2C gene cluster and VKORC1 regions was significantly associated with dose after correction for multiple testing. During initiation of therapy, homozygosity for CYP2C9 and VKORC1 variant alleles increased the risk of over-anticoagulation, hazard ratios 21.84 (95% CI 9.46; 50.42) and 4.56 (95% CI 2.85; 7.30), respectively. One of 8 patients with CYP2C9*3/*3 (12.5%) experienced severe bleeding during the first month compared with 0.27% of other patients (P = .066). A multiple regression model using the predictors CYP2C9, VKORC1, age, sex, and druginteractions explained 59% of the variance in warfarin dose, and 53% in an independent sample of 181 Swedish individuals. In conclusion, CYP2C9 and VKORC1 significantly influenced warfarin dose and predicted individuals predisposed to unstable anticoagulation. Our results strongly support that initiation of warfarin guided by pharmacogenetics would improve clinical outcome.This publication has 52 references indexed in Scilit:
- Genotypes of vitamin K epoxide reductase, γ-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patientsThrombosis Research, 2007
- Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral AnticoagulationCirculation, 2007
- Pharmacogenetics of warfarin: regulatory, scientific, and clinical issuesJournal of Thrombosis and Thrombolysis, 2007
- Influence of CYP2C9 and VKORC1 1173C/T Genotype on the Risk of Hemorrhagic Complications in African-American and European-American Patients on WarfarinClinical Pharmacology & Therapeutics, 2007
- Association of warfarin dose with genes involved in its action and metabolismHuman Genetics, 2006
- Effect ofVKORC1Haplotypes on Transcriptional Regulation and Warfarin DoseThe New England Journal of Medicine, 2005
- Internet based clinical trial protocols - as applied to a study of warfarin pharmacogeneticsBritish Journal of Clinical Pharmacology, 2004
- Haploview: analysis and visualization of LD and haplotype mapsBioinformatics, 2004
- Pedigree disequilibrium tests for multilocus haplotypesGenetic Epidemiology, 2003
- Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complicationsThe Lancet, 1999